Kura Oncology, Inc.
KURA
$5.95
$0.223.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 54.33% | -- | -- | -- | -- |
| Gross Profit | -15.43% | -- | -- | -- | -- |
| SG&A Expenses | 25.58% | 69.17% | 38.30% | 41.08% | 59.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.73% | 63.25% | 40.99% | 41.00% | 48.91% |
| Operating Income | -18.82% | 51.98% | -40.99% | -41.00% | -48.91% |
| Income Before Tax | -15.50% | 59.80% | -40.94% | -36.75% | -45.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.96% | 55.09% | -40.94% | -36.75% | -45.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.96% | 55.09% | -40.94% | -36.75% | -45.37% |
| EBIT | -18.82% | 51.98% | -40.99% | -41.00% | -48.91% |
| EBITDA | -18.89% | 52.20% | -41.22% | -41.25% | -49.11% |
| EPS Basic | -11.30% | 60.14% | -25.19% | -10.18% | -18.51% |
| Normalized Basic EPS | -10.87% | 48.42% | -25.19% | -10.15% | -18.50% |
| EPS Diluted | -11.30% | 60.14% | -25.19% | -10.18% | -18.51% |
| Normalized Diluted EPS | -10.87% | 48.42% | -25.19% | -10.15% | -18.50% |
| Average Basic Shares Outstanding | 4.18% | 12.67% | 12.57% | 24.13% | 22.66% |
| Average Diluted Shares Outstanding | 4.18% | 12.67% | 12.57% | 24.13% | 22.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |